Global Glioma Therapeutics Market: Analysis & Forecast 2019-2023 - Strategic Alliances to Drive Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 8, 2019--The “Global Glioma Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The glioma therapeutics market will register a CAGR of more than 9% by 2023.
Strategic alliances to drive growth in the market
Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma.
Expected approval of late-stage pipeline molecules
As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
Availability of alternative therapies
Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients’ inclination toward the surgical and radiation treatment options.
Key PlayersF. Hoffmann-La Roche Merck Sharp & Dohme Mylan NextSource Biotechnology Novartis
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCTMarket segmentation by product Comparison by product Small molecules - Market size and forecast 2018-2023 Biologics - Market size and forecast 2018-2023 Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPEGeographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPEOverview Landscape disruption Competitive scenario
PART 12: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors F. Hoffmann-La Roche Merck Sharp & Dohme Mylan NextSource Biotechnology Novartis
For more information about this report visit https://www.researchandmarkets.com/research/97lwgq/global_glioma?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190108005842/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/08/2019 11:38 AM/DISC: 01/08/2019 11:38 AM